[
  {
    "symbol": "PROK",
    "price": 9.91,
    "beta": 0,
    "volAvg": 333495,
    "mktCap": 2330118619,
    "lastDiv": 0,
    "range": "5.14-14.19",
    "changes": -0.06,
    "companyName": "ProKidney Corp.",
    "currency": "USD",
    "cik": "0001850270",
    "isin": null,
    "cusip": null,
    "exchange": "NASDAQ Capital Market",
    "exchangeShortName": "NASDAQ",
    "industry": "Biotechnology",
    "website": "https://www.prokidney.com",
    "description": "ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.",
    "ceo": "Dr. Timothy A. Bertram D.V.M., Ph.D.",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "87",
    "phone": "336 999 7028",
    "address": "2000 Frontis Plaza Blvd.",
    "city": "Winston-Salem",
    "state": "NC",
    "zip": "27103",
    "dcfDiff": null,
    "dcf": 0,
    "image": "https://financialmodelingprep.com/image-stock/PROK.png",
    "ipoDate": "2021-06-30",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]